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ABSTRACT
Bioassays are currently used to measure the presence of functionally active cytokines in biological fluids. These 
assays may be influenced by the presence o f other substances, either cytokine specific or not, in such fluids. In 
the present study, we analyzed whether some currently used disease-modifying antirheumatic drugs 
(DMARDs) could interfere with the measurements of circulating interleukin-6 (IL-6) bioactivity in the B9 
hybridoma assay. When sera from healthy controls and patients treated with various DMARDs, such as 
azathioprine (AZA), methotrexate (MTX), intramuscular gold, and sulfasalazine (SASP), were tested in the 
IL-6 bioassay, an inhibitory effect was observed only with sera from patients treated with AZA. Addition of 
exogenous AZA, 6-mercaptopurine (6-MP), and MTX to the IL-6 bioassay resulted in a dose-dependent 
inhibition of the B9 cell proliferation induced by IL-6, AZA being most potent on a molar basis. Concentrations 
of AZA and 6-MP compatible with serum concentrations achieved in RA patients were able to inhibit the 
bioassay, but this was not the case for MTX. Exogenous SASP and its metabolites did not modify the 
IL-6-induced B9 celt proliferation. This study shows that circulating AZA (or its metabolites) exert an 
inhibitory effect in the IL-6 bioassay. This method is therefore not suitable to measure IL-6 concentrations in 
patients treated with AZA. Interference o f drugs must be ruled out when bioassays are used to evaluate 
cytokine levels in biological fluids.
INTRODUCTION
The biological effects of interleukin-6 (IL-6) suggest a rele­vant role in the pathogenesis o f rheumatoid diseases. IL-6 
is the major inducer of acute phase protein synthesis, it is 
implicated in T lymphocyte proliferation, B lymphocyte differ­
entiation, immunoglobulin production, and hemato- and throm- 
bopoiesis (1). IL-6 shares proinflammatory effects with cyto­
kines such as interleukin-1 (IL-1) and tumor necrosis factor 
(TNF), which in turn induce its production (2,3), Furthermore, 
IL-6 possesses antiinflammatory properties such as the induc­
tion of tissue inhibitor of metalloproteinases-1 (4,5) and the 
inhibitory effect on of IL-1 and TN F production (6). IL-6 is
produced by rheumatoid synovium (7-9) and is found at high 
concentrations in synovial fluid (SF) of patients with rheuma­
toid arthritis (RA) (10-12) correlating with local (10,13) and 
systemic (13) parameters of disease activity. Circulating IL-6 
concentrations in RA also correlate with acute phase parameters 
(10,11) and though it is probable that the inflamed joint is the 
main production site of IL-6 in RA, measurements of circulat­
ing IL-6 are more suitable for follow-up studies.
Some evidence suggests that treatment with different dis­
ease-modifying antirheumatic drugs (DMARDs) affects circu­
lating IL-6 concentrations in RA. Decreases in circulating IL-6 
have been observed during treatment with intramuscular (14) 
and oral gold (15), methotrexate (16) and cyclosporin (17),
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while for sulfasalazine (SASP) contradictory results have been 
reported (15,18). In a randomized, 48-week, double-blind trial 
conducted in our center (19), methotrexate (MTX) proved to be 
superior to azathioprine (AZA) in the treatment of active rheu­
matoid arthritis (RA). In these patients, treatment with both 
DMARDs resulted in significant decreases of circulating con­
centrations of IL-6 bioactivity, but, unexpectedly this decrease 
was much more marked and occurred earlier in patients treated 
with AZA and in the group of patients that did not experience 
clinical improvement (more often treated with this drug). MTX, 
in contrast, induced a more pronounced decrease than AZA 
when IL-6 was assessed by means of an immunoassay (20). 
Therefore, it seemed that a factor present in the circulation of 
patients treated with AZA, but not with MTX, exerted an inhib­
itory effect in the IL-6 bioassay. Since this factor might be the 
trial drug, we studied the effects of MTX, AZA, and SASP, 
three currently used DMARDs, in the measurements of IL-6 
bioactivity.
METHODS
IL-6 bioassay
Iscove’s modified Dulbecco’s medium (IMDM) supple­
mented with 5% fetal calf serum (PCS), penicillin (100 lU/ml), 
streptomycin (100 |xg/ml), and 2-mercaptoethanol (5 x  10-5 
M] constituted the B9 culture medium. The IL-6 bioassay was 
performed as previously described (21). Briefly, 5000 B9 cells 
in culture medium were seeded in 96-well flat bottom microtiter 
plates (Costar, 1170 AB Badhoevedorp, The Netherlands) in 
the presence of known amounts o f recombinant human IL-6 
(rhu IL-6) (kind gift o f Prof. L. A. Aarden, CLB Amsterdam, 
The Netherlands) or diluted samples (usual dilution range 1/20— 
1/160). Cell proliferation was measured by thymidine incorpo­
ration after 64 h (7.4 kBq [3H]thymidine/well). When indi­
cated, a colorimetric method that measures the conversion of 
MTT [3-(4,5-dimethyl-thiazol-2yl)-2,5-diphenyl tétrazolium 
bromide, Sigma M-5655] to formazan by living cells (22) was 
additionally used. One unit/ml IL-6 was defined as the concen­
tration that leads to half-maximal thymidine incorporation (or 
conversion from MTT to formazan). The sensitivity of this 
assay is 0.3 U/ml. Cell viability was judged by the trypan blue 
exclusion test.
Effect o f circulating DMARDs in the IL-6 bioassay
Serum from healthy controls or RA patients treated with 
different DMARDs was added to B9 cells cultured in the pres­
ence of serial dilutions of rhu IL-6. Sera from patients treated 
with MTX (n =  4), AZA (n =  4), salazopyrin (SASP) (n =  2), 
intramuscular gold {n =  2), or only nonsteroidal antiinflamma­
tory drugs (NSAIDs) (n =  2) were tested. The sera were heat 
inactivated for 30 min at 56°C, diluted in B9 culture medium, 
and tested in 2-fold dilutions (final dilution range 1/20-1/ 
1280). The control consisted of B9 cells cultured with rhu IL-6 
in the absence of sera. Cell proliferation was measured by 
[3H]thymidine incorporation as indicated above.
Effect o f exogenous AZA, MTX, sulfasalazine (SASP), 
and their metabolites in the IL-6 bioassay
The drugs tested were MTX (Pharmachemie, Haarlem, The 
Netherlands) alone or in combination with folinic acid (Lederle, 
Etten-Leur, The Netherlands), AZA (Wellcome, Weesp, The 
Netherlands) and its main metabolite 6-mercaptopurine (6-MP) 
(kind gift of Dr. R. A. d’Abreu, Nijmegen, The Netherlands), 
and sulfasalazine (SASP) and its main metabolites sulfapyri- 
dine, acetyl-sulfapyridine, and 5-aminosalicylic acid (5-ASA) 
(Pharmacia, Upsala, Sweden). For reference, the circulating 
concentrations of these drugs are shown in Table 1. The drugs 
were diluted in B9 culture medium (final concentration range 
1 0 '3 to 10“ 12 M) and added to B9 cells cultured in the presence
T able 1. D oses and  C irculating  Concentrations of MTX, AZA, SASP, and Main  M etabolites during
T reatment of RA Patients“
Circulating concentrations o f DMARDs and Inhibitory concentrations
DMARD Usual doses in RA metabolites measured in RA patients (Cmax) in the B9 bioassayh
MTX 7.5-15 mg weekly in  1 or 3 
doses
MTX (25 f 5.8 ±  1.2 x  10-7 M  after 5 h, 
0.13 ± 0 .0 5  x  10“ 7 M after 
30 h
3= 10~7 Af
A ZA 100-200 mg daily in 2-3 doses A ZA (26) 5-50 X 10-9  M  for up to 6 h 
after a dose o f 50 mg
2= 10 ~ l 2M
6-MP (26) 20-100 x  10-9  M  for up to 6 h 
after a dose o f  50 mg
5= 10~ 10 M
SASP 2-3 g daily in 2 -4  doses SASP (27) 8-118 x  10“ 6 M  after 2-8 h NI
SP (27) 31-88 X 10_ 6 M  after 10-30 h NI
AcSP (27) 15-66 x  10~6 Ai after 11-31 h NI
5ASA (27) ND NI
aMTX, methotrexate; AZA, azathioprine; 6-MP, 6 mercaptopurine; SASP, sulfasalazine; SP, sulfapyridine; AcSP, acetylsulfapyridine; 5ASA, 
5 aminosalicylic acid; NI, no inhibition observed at the concentrations tested (1 0 '3 to 10"12 M)\ ND, not detectable in the circulation. 
bResults from the present study.
“Reference numbers in parentheses.
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of 5 U/ml rhu IL-6. The control consisted o f B9 cells cultured 
with 5 U/ml rhu IL-6 in culture medium. Cell proliferation was 
measured by [3H]thymidine incorporation and additionally by a 
colorimetric method (22) when MTX was tested.
RESULTS
In flu en ce  o f  c ircu la tin g  d ru g s  in  the IL -6  b ioassay
When sera from patients treated with AZA (n =  4) were 
added to B9 cells cultured with exogenous IL-6, an inhibition of 
the cell proliferation was observed. This inhibition was dose 
dependent (Fig. 1A) and still observed at serum dilutions of 
approximately 1/1300. Sera from healthy controls or patients 
treated with MTX, SASP, intramuscular gold, or NSAIDs en-
A
thousands cpm
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- -H -  M m  1 /320  - A -  U 640 - X -  1/12&0
B
thousands cpm
IL-6 Units/ml
"  C O N T R O L  -■-»- N O  D R U G  N S A I D
-Cl- M i x  - X  G O L D  -0 - S A S P
FIG . 1. Effect o f serum from patients treated with different 
DMARDs on the B9 bioassay. Control: B cells cultured with 
IL-6 in B9 medium. (A) Serum from one patient treated with 
100 mg/day AZA was added at different dilutions (range 1/20— 
1/1280) to B9 cells cultured with IL-6. (B) Serum from one 
healthy control (no drugs) and patient treated with other 
DMARDs or NSAIDs was added to B9 cells cultured with IL-6 
(dilution 1/20),
hanced the B9 cell proliferation induced by low IL-6 concentra­
tions reflecting the presence of endogenous IL-6 in these sera 
(Fig. IB).
Effect of exogenous AZA, MTX, SASP, and their 
metabolites in the IL-6 bioassay
Among the drugs tested, AZA, 6-MP, and MTX (Fig. 2A) 
resulted in a dose-dependent inhibition the B9 proliferation 
induced by IL-6. This effect was not due to drug-induced cell 
toxicity (assessed by trypan blue exclusion). On a molar basis 
AZA and 6-M P were more potent than MTX since significant 
inhibition occurred with concentrations > 1 0 “ 12 M  for AZA, 
&10~10 M  fo r 6MP, and & H T 7 M  for MTX, respectively.
A
Concentration DMARD (log molar)
AZA C Z lB M P  tZ U  MTX MTT MTX
B
FIG. 2. Effects of exogenous DMARDs on the B9 bioassay. 
The control consisted of B9 cells cultured without DMARDs 
and is set at 100%; 5 U/ml rhu IL-6 was added to all cultures. 
(A) Effect of different concentrations o f AZA, 6-M P, and MTX 
on the B9 cell proliferation measured by [3H]thymidine uptake. 
A colorimetric method was additionally used for M TX (MTX 
MTT). Results show the average of 3 experiments. Drug con­
centration (log molar) is on the x  axis; cell proliferation (as 
percentage of the control) is on the y axis. (B) Rescue effect of 
folinic acid on the inhibition of B9 cell proliferation induced by 
MTX. Proliferation was measured by a colorimetric method 
(MTT). Results represent the average of 3 experiments. M TX 
concentration (log molar) is on the x  axis; folinic acid concen­
tration (log molar) is on the z axis; cell proliferation (as percent­
age of the control) is on the y axis.
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Low concentrations o f MTX (1 0 "v M ) resulted in an increased 
thymidine uptake by the B9 cells but had little or no effect when 
cell proliferation was assessed by a colorimetric method. No 
effect on the cell proliferation was observed after addition of 
SASP or its metabolites (Table 1). Folinic acid alone did not 
affect cell proliferation, but when added together with MTX (at 
approximately lOOx molar excess) reversed the inhibition 
caused by this drug (Fig. 2B).
DISCUSSION
Bioassays are currently used to quantitate cytokines in a 
variety of diseases since they provide information not only 
about the presence but also about the functional activity of 
cytokines in biological fluids. These assays may be hampered 
by the presence of inhibitors, either cytokine-specific or not. 
The influence of drugs present in biological fluids on cytokine 
bioassays has been suggested by other authors (23), but this is, 
to our knowledge, the first report about interference of a circu­
lating DMARD with measurements o f IL-6 bioactivity. The 
interference of AZA was first observed in a clinical study (20) 
and corroborated herein by in vitro evidence.
The effect of different sera in the IL-6 bioassay was first 
studied. Only sera from patients treated with AZA resulted in a 
dose-dependent inhibition o f the B9 cell growth induced by 
IL-6, When different DMARDs and their metabolites were 
exogenously added to the bioassay only the drugs with cyto­
static properties (AZA, 6-MP, and MTX) resulted in a dose- 
dependent inhibition o f the B9 cell proliferation induced by 
IL-6. SASP and its metabolites did not alter the bioassay.
Considering the serum levels o f 6-M P, AZA, and MTX 
achieved in RA patients (Table 1) and the sample dilution in the 
bioassay (range 1/20-1/160), it is clear that samples from pa­
tients treated with AZA yield concentrations of this drug and its 
metabolite that will inhibit the B9 cell proliferation while this is 
not true for patients treated with MTX. The increased thymi­
dine uptake observed with nanomolar concentrations of MTX is 
probably due to inhibition of thymidilate synthetase by MTX 
(24). Caution with sample timing is advisable, since nanomolar 
MTX concentrations could be attained in the bioassay if sam­
ples taken shortly after MTX intake are used.
Taken together, our results show that the B9 bioassay is not 
suitable to measure IL-6 in patients treated w ith AZA. Treat­
ment with MTX, SASP, and intramuscular gold did not seem to 
interfere with this assay. The general implication is that when 
cytokine bioassays are used in clinical studies, the effects of 
circulating drugs in the bioassays should first be tested.
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